Efficacy and safety of simeprevir with pegylated interferon alfa-2b and ribavirin in kidney transplant patients with chronic hepatitis C
Not Applicable
- Conditions
- Patients with chronic hepatitis C virus infection
- Registration Number
- JPRN-UMIN000013088
- Lead Sponsor
- Osaka University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 18
Inclusion Criteria
Not provided
Exclusion Criteria
1) Co-infection with hepatitis B virus 2) Co-infection with anti-human immunodeficiency virus 3) Other forms of liver disease (alcohol liver disease, autoimmune hepatitis etc.) 4) Decompensated cirrhosis, Liver failure 5) Contraindication to pegylated interferon 6) Contraindication to ribavirin
Study & Design
- Study Type
- Interventional,observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Sustained virologic response rate 12(SVR12)
- Secondary Outcome Measures
Name Time Method